• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products

    Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products

    MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights.

    The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 22nd Century is focusing on smoker health and wellness by giving smokers an opportunity to control their tobacco consumption.

    "During 2025, we executed a strategic pivot toward higher-margin branded products, expanded partnerships with established retail chains, and developed a new tobacco harm reduction category, all of which we continue to build upon in 2026. With multiple VLN® and partner product formats now actively selling in the market, we are especially focused on steadily expanding the number of retail chains and total outlets carrying VLN® products," said Larry Firestone, CEO of 22nd Century Group.

    Firestone continued, "Our strategy and business model now enable tobacco companies of any size to adopt a Partner VLN® or licensing pathway with speed and scalability. For the first time, this creates a viable model for the industry to broaden the reach of VLN® products and meaningfully deliver on its stated commitment to tobacco harm reduction."

    "We also made important progress in 2025 to strengthen our financial position as we shifted our focus from restructuring to growth. We exited the year debt-free, with a more efficient operating structure and sufficient capital to support our near-term growth objectives. During the year, we eliminated over $8.0 million of legacy debt through repayment, settlement, and exchange, improving our balance sheet and reducing our cost base. In addition, we finalized our insurance claim related to the 2022 Grass Valley facility fire, securing a $9.5 million non-dilutive settlement at a critical point in our transition."

    "As we move through 2026, we are executing with a clear strategic growth focus, supported by a strengthened financial and operational foundation. Our priorities include expanding VLN® retail distribution and consumer awareness, scaling toward profitability, and maintaining active engagement with FDA regulators and public health stakeholders both domestically and internationally."

    Fourth Quarter 2025 Financial Results (compared to Third Quarter 2025, except as noted)

    All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company's hemp/cannabis business in late 2023, except as noted.

    • Net revenues decreased slightly to $3.5 million from $4.0 million.
    • Gross profit (loss) improved to $(0.8) million, compared to $(1.1) million.
    • Operating expenses were $2.0 million, decreased from $2.2 million.
    • Operating loss decreased to $2.8 million, compared to $3.2 million.
    • Net loss was $2.8 million, compared to net loss of $3.8 million.
    • Adjusted EBITDA loss was $2.4 million, compared to a loss of $2.9 million.
    • Ended the calendar year 2025 with cash of $7.1 million.



    Recent Business Highlights

    • Maintained a strong balance sheet, ending the year with no outstanding debt and $7.1 million in cash available for operations.
    • Continued to expand market access to both VLN® and Partner VLN® products, as well as new natural style cigarette products, with expanded store availability
    • Further increased state authorizations to support expanded access to the Company's branded products, including:
      • 22nd Century VLN® – 48 States
      • Pinnacle® VLN® – 42 States
      • Pinnacle® – 45 States
      • Smoker Friendly VLN® – 43 States
      • Smoker Friendly – 47 States
      • Smoker Friendly Black Label (Tobacco & Water) – 39 states
    • Increased Pinnacle® VLN® availability to almost 1,500 stores within a top-5 convenience store chain across 12 states; full rollout across all remaining store locations is expected in next 90 days supported by in-store marketing materials and digital promotion programs.
    • Continued to advance negotiations with new customers to expand VLN® distribution and launch additional VLN® partner brands, further diversifying the reduced nicotine content product category.
    • Continued to advance initiatives aimed at margin expansion through mix improvement, operating cost efficiency and capital allocation.
    • Moved forward on plans to introduce 100mm format VLN® cigarettes and additional international combustible products tailored to consumer preferences in those markets.



    Fourth Quarter 2025 Product Line Net Revenues

    • Cigarette net revenues were $2.6 million, increased from $2.5 million in the third quarter of 2025, reflecting an increase in certain customer pricing incentives, offset by increased CMO volumes. Additional expansion of new natural style cigarette products launched in 2025 will continue to accelerate revenue and margin growth in this category.
    • Filtered cigar net revenues were $0.4 million compared to $1.3 million, reflecting ongoing shifting product mix and decreasing volume from remaining CMO customers.
    • Distribution net revenues from other tobacco products, consisting of Pinnacle branded moist snuff and cigarillos were $0.4 million compared to negligible amounts in the third quarter 2025.
    • VLN® cigarette net revenues were $0.1 million, reflecting continuing placements of VLN® and partner VLN® products, offset by customer returns and product exchanges to the new VLN® branding. Total new branded VLN® and partner VLN® products shipped in the fourth quarter were approximately 8,800 cartons.



    Balance Sheet

    • The Company reported zero long-term debt, having extinguished its remaining senior secured debt in full during 2025.
    • Cash and equivalents were $7.1 million at quarter end.
    • Inventories were $4.3 million, increased from $2.9 million at third quarter end, reflecting increases in reduced nicotine content tobacco leaf.



    Conference Call

    22nd Century will host a live webcast today at 8:00 a.m. E.T. to discuss its fourth quarter and full year 2025 financial results and business highlights. The live and archived webcast will be accessible in the Events section on 22nd Century's Investor Relations website at https://ir.xxiicentury.com/events.

    Summary Financial Results

    (dollars in thousands, except per share data)

      Three Months Ended
      December 31,  Change
      2025  2024  $%
    Revenues, net $3,537  $4,020  (483)(12.0)
    Gross loss $(834) $(1,254) 420 (33.5)
    Operating loss $(2,803) $(4,091) 1,288 (31.5)
    Net loss from continuing operations $(2,783) $(4,246) 1,463 (34.5)
    Basic and diluted loss per common share from continuing operations $(5.89) $(3,257.47) 3,251.58 (99.8)
    Adjusted EBITDA (a) $(2,387) $(3,888) 1,501 38.6 



      Year Ended
      December 31,  Change
      2025  2024  $%
    Revenues, net $17,587  $24,382  (6,795)(27.9)
    Gross loss $(3,137) $(2,400) (737)30.7 
    Operating loss $(11,566) $(13,950) 2,384 (17.1)
    Net loss from continuing operations $(13,117) $(15,495) 2,378 (15.3)
    Basic and diluted loss per common share from continuing operations $(71.26) $(27,812.56) 27,741.30 (99.7)
    Adjusted EBITDA (a) $(10,233) $(13,137) 2,904 22.1 
              
    (a) Adjusted EBITDA is a non-GAAP financial measure. Please see "Notes Regarding Non-GAAP Financial Information" for additional information regarding our use of non-GAAP financial measures. Refer to Tables A at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.



    Summary Product Line Results


    (in thousands)

      Three Months Ended
      December 31,    
      2025 2024  Change
      $Cartons $Cartons $Cartons
    Contract manufacturing         
    Cigarettes 2,648155 3,276 228  (628)(73)
    Filtered cigars 40651 833 112  (427)(61)
    Other tobacco products 35440 - -  354 40 
    Total contract manufacturing 3,408246 4,109 340  (701)(94)
    VLN® 1292 (89)(2) 218 4 
    Total product line revenues 3,537248 4,020 338  (483)(90)



      Year Ended
      December 31,    
      2025 2024 Change
      $Cartons $Cartons $Cartons
    Contract manufacturing         
    Cigarettes 12,8971,525 14,219 644 (1,322)881 
    Filtered cigars 4,110549 9,427 1,361 (5,317)(812)
    Other tobacco products 44254 756 120 (314)(66)
    Total contract manufacturing 17,4492,128 24,402 2,125 (6,953)3 
    VLN® 1384 (20)- 158 4 
    Total product line revenues 17,5872,132 24,382 2,125 (6,795)7 



    About 22nd Century Group, Inc.

    22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

    Our Technology is Tobacco

    Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

    Our Products

    We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

    FDA Authorization and Scientific Foundation

    VLN® low nicotine combustible cigarettes were authorized in December 2021, making them the first and still the only combustible cigarettes authorized by the U.S. Food and Drug Administration specifically to help reduce nicotine consumption.

    Decades of independent clinical research and peer-reviewed studies—evaluated as part of the FDA's Modified Risk Tobacco Product (MRTP) authorization process—demonstrated that reducing nicotine content can decrease nicotine intake, increase quit attempts, and reduce overall exposure to nicotine.

    FDA-authorized VLN® claims include:

    • "95% less nicotine"
    • "Helps reduce your nicotine consumption"
    • "Greatly reduces your nicotine consumption"
    • "Helps you smoke less"



    VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.

    Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

    Learn more about VLN® at tryvln.com.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 26, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Notes regarding Non-GAAP Financial Information

    In addition to the Company's reported results in accordance with generally accepted accounting principles in the United States of America ("GAAP"), the Company provides EBITDA and Adjusted EBITDA.

    In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.

    The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company's measurement of Adjusted EBITDA may not be comparable to those of other companies.

    Investor Relations & Media Contact

    Matt Kreps

    Investor Relations

    22nd Century Group

    [email protected]

    214-597-8200

    22nd CENTURY GROUP, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (amounts in thousands, except share and per-share data)

      December 31,  December 31, 
      2025  2024 
    ASSETS      
    Current assets:      
    Cash and cash equivalents $7,149  $4,422 
    Accounts receivable, net  3,594   1,698 
    Inventories  4,326   2,015 
    Insurance recoveries  —   768 
    GVB promissory note, net  —   500 
    Prepaid expenses and other current assets  2,562   1,068 
    Current assets of discontinued operations held for sale  —   1,051 
    Total current assets  17,631   11,522 
    Property, plant and equipment, net  2,440   2,773 
    Operating lease right-of-use assets, net  728   1,639 
    Intangible assets, net  6,224   5,724 
    Other assets  —   15 
    Total assets $27,023  $21,673 
           
    LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY      
    Current liabilities:      
    Notes and loans payable-current $204  $254 
    Current portion of long-term debt  —   1,500 
    Operating lease obligations  168   261 
    Accounts payable  1,000   2,401 
    Accrued expenses and other current liabilities  836   1,439 
    Accrued litigation  —   768 
    Accrued excise taxes and fees  3,343   2,038 
    Contract liabilities  1,721   20 
    Current liabilities of discontinued operations held for sale  —   1,281 
    Total current liabilities  7,272   9,962 
    Long-term liabilities:      
    Notes and loans payable  504   — 
    Operating lease obligations  601   1,437 
    Long-term debt  —   5,165 
    Other long-term liabilities  154   1,097 
    Total liabilities  8,531   17,661 
           
    Mezzanine equity:      
    Series A convertible preferred shares, $0.00001 par value; 10,000,000 shares authorized, 9,650 shares issued and outstanding at December 31, 2025 and 0 at December 31, 2024, respectively  2,734   — 
    Total mezzanine equity  2,734   — 
           
    Shareholders' equity:      
    Common stock, $.00001 par value, 500,000,000 shares authorized, 510,384 shares issued and outstanding at December 31, 2025 and 2,285 at December 31, 2024, respectively      
    Common stock, par value  —   — 
    Capital in excess of par value  414,683   397,883 
    Accumulated deficit  (398,925)  (393,871)
    Total shareholders' equity  15,758   4,012 
    Total liabilities, mezzanine equity and shareholders' equity $27,023  $21,673 



    22nd CENTURY GROUP, INC.


    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

    (amounts in thousands, except share and per-share data)

     Year Ended
     December 31, 
     2025  2024 
    Revenues, net$17,587  $24,382 
    Cost of goods sold 10,186   14,278 
    Excise taxes and fees on products 10,538   12,504 
    Gross loss (3,137)  (2,400)
    Operating expenses:     
    Sales, general and administrative 7,591   10,287 
    Research and development 688   1,133 
    Other operating expense, net 150   130 
    Total operating expenses 8,429   11,550 
    Operating loss from continuing operations (11,566)  (13,950)
    Other income (expense):     
    Other income (expense), net (207)  507 
    Interest income 83   72 
    Interest expense (1,455)  (2,094)
    Total other income (expense), net (1,579)  (1,515)
    Loss from continuing operations before income taxes (13,145)  (15,465)
    (Benefit) provision for income taxes (28)  30 
    Net loss from continuing operations$(13,117) $(15,495)
          
    Discontinued operations:     
    Income from discontinued operations before income taxes$8,063  $331 
    Provision for income taxes —   — 
    Income from discontinued operations$8,063  $331 
          
    Net loss$(5,054) $(15,164)
    Comprehensive loss$(5,054) $(15,164)
          
    Net loss$(5,054) $(15,164)
    Deemed dividends (4,679)  (10,303)
    Net loss available to common shareholders$(9,733) $(25,467)
          
    Basic and diluted income (loss) per share:     
    Basic and diluted loss per common share from continuing operations$(71.26) $(27,812.56)
    Basic and diluted income per common share from discontinued operations$43.81  $594.83 
    Basic and diluted loss per common share from deemed dividends$(25.42) $(18,493.32)
    Basic and diluted loss per common share$(52.87) $(45,711.05)
          
    Weighted average shares outstanding - basic and diluted 184,067   557 



    Table A – Reconciliations of Non-GAAP Measures


    (dollars in thousands, except share and per-share data)

    Below is a table containing information relating to the Company's Net loss, EBITDA and Adjusted EBITDA for the years ended December 31, 2025 and 2024, including a reconciliation of these Non-GAAP measures for such periods.

      Quarter Ended
      December 31, 
      Amounts in thousands ($000's)
      except share and per share data
      (UNAUDITED)
             $ Change 
      2025  2024   fav / (unfav)1
    Net loss from continuing operations $ (2,783) $ (4,246) $ 1,463 
    Interest (income)/expense, net  (25)  221   (246)
    Provision (benefit) for income taxes  5   3   2 
    Amortization and depreciation  218   241   (23)
    EBITDA $ (2,585) $ (3,781) $ 1,196 
    Adjustments:         
    Restructuring and impairment  —   (111)  111 
    Change in fair value of derivative liabilities  —   (75)  75 
    Change in fair value of warrant liabilities  —   (68)  68 
    Equity-based employee compensation expense  198   147   51 
    Adjusted EBITDA $ (2,387) $ (3,888) $ 1,501 
              
    Adjusted EBITDA loss per common share $(5.05) $(2,982.89) $2,977.84 
    Weighted average common shares outstanding - basic and diluted  472,290   1,304    



      Year Ended
      December 31, 
      Amounts in thousands ($000's)
      except share and per share data
      (UNAUDITED)
             $ Change 
      2025  2024   fav / (unfav)1
    Net loss from continuing operations $ (13,117) $ (15,495) $ 2,378 
    Interest (income)/expense, net  1,372   2,022   (650)
    Provision (benefit) for income taxes  (28)  30   (58)
    Amortization and depreciation  912   1,003   (91)
    EBITDA $ (10,861) $ (12,440) $ 1,579 
    Adjustments:         
    Restructuring and impairment  —   (459)  459 
    Inventory write-down  —   431   (431)
    Change in fair value of derivative liabilities  —   (557)  557 
    Change in fair value of warrant liabilities  207   (492)  699 
    Equity-based employee compensation expense  421   380   41 
    Adjusted EBITDA $ (10,233) $ (13,137) $ 2,904 
              
    Adjusted EBITDA loss per common share $(55.59) $(23,580.59) $23,525.00 
    Weighted average common shares outstanding - basic and diluted  184,067   557    



    1
    Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA



    Primary Logo

    Get the next $XXII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group to Announce Fourth Quarter and Full Year 2025 Results on March 26, 2026

    MOCKSVILLE, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, will host a webcast on Thursday, March 26, 2026, at 8:00 AM ET to discuss its 2025 fourth quarter and full year results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results, discuss progress made in the recent months and update plans for the 2026 year. The live and archived webcast will

    3/23/26 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Continued Early Sales Momentum for VLN® Cigarette Products

    Expansion in 2026 Forecasted to Exceed 5,000 Retail Outlets Nationwide as Consumers Demonstrate Interest in VLN® Brands VLN® Remains the Only FDA-Authorized Combustible Cigarette Designed to Reduce Nicotine Consumption MOCKSVILLE, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced continued early sales momentum for its VLN® low nicotine cigarette products in the U.S. market. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 22n

    2/23/26 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    SEC Filings

    View All

    SEC Form 8-K filed by 22nd Century Group Inc.

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    3/26/26 8:02:51 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by 22nd Century Group Inc.

    10-K - 22nd Century Group, Inc. (0001347858) (Filer)

    3/26/26 6:10:33 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    3/24/26 1:57:09 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Arno Andrew was granted 17,295 shares, increasing direct ownership by 9,298% to 17,481 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/14/25 4:58:49 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP of Sales and Marketing Manfredonia Robert P was granted 32,429 shares, increasing direct ownership by 5,123% to 33,062 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:40:01 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    VP and Deputy General Counsel Staffeldt Jonathan was granted 37,146 shares, increasing direct ownership by 5,124% to 37,871 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:38:22 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

    BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

    9/12/22 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care